Next Article in Journal
Efforts at COVID-19 Vaccine Development: Challenges and Successes
Previous Article in Journal
DNA Vaccine Development at Pre- and Post-Operation Warp Speed
Editorial

Meningococcal Vaccines: Challenges and Prospects

1
Center for Drug Delivery Research, Vaccine Nanotechnology Laboratory, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA
2
Fraunhofer USA Center for Molecular Biotechnology, Newark, DE 19711, USA
3
College of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Vaccines 2020, 8(4), 738; https://doi.org/10.3390/vaccines8040738
Received: 5 November 2020 / Accepted: 5 November 2020 / Published: 4 December 2020
Note: In lieu of an abstract, this is an excerpt from the first page.

Neisseria meningitidis is a gram-negative bacterium that causes a severe acute infection, called the meningococcal disease [...] View Full-Text
MDPI and ACS Style

Bagwe, P.; Bajaj, L.; Gala, R.; Zughaier, S.M.; Uddin, M.N.; D’Souza, M.J. Meningococcal Vaccines: Challenges and Prospects. Vaccines 2020, 8, 738. https://doi.org/10.3390/vaccines8040738

AMA Style

Bagwe P, Bajaj L, Gala R, Zughaier SM, Uddin MN, D’Souza MJ. Meningococcal Vaccines: Challenges and Prospects. Vaccines. 2020; 8(4):738. https://doi.org/10.3390/vaccines8040738

Chicago/Turabian Style

Bagwe, Priyal, Lotika Bajaj, Rikhav Gala, Susu M. Zughaier, Mohammad N. Uddin, and Martin J. D’Souza 2020. "Meningococcal Vaccines: Challenges and Prospects" Vaccines 8, no. 4: 738. https://doi.org/10.3390/vaccines8040738

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop